Astria Therapeutics (NASDAQ:ATXS) Receives Buy Rating from HC Wainwright

Astria Therapeutics (NASDAQ:ATXS)‘s stock had its “buy” rating reissued by investment analysts at HC Wainwright in a research note issued to investors on Tuesday,Benzinga reports. They presently have a $16.00 target price on the biotechnology company’s stock. HC Wainwright’s price target suggests a potential upside of 57.48% from the company’s previous close.

Several other equities analysts have also issued reports on the company. Oppenheimer upped their target price on Astria Therapeutics from $26.00 to $28.00 and gave the company an “outperform” rating in a report on Thursday, November 14th. Evercore ISI raised shares of Astria Therapeutics to a “strong-buy” rating in a report on Wednesday, August 14th. Finally, Wedbush restated an “outperform” rating and issued a $22.00 target price on shares of Astria Therapeutics in a research note on Tuesday, August 13th. Five investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of “Buy” and an average target price of $25.60.

Astria Therapeutics Price Performance

Shares of NASDAQ:ATXS traded up $0.11 during trading on Tuesday, reaching $10.16. 34,080 shares of the stock were exchanged, compared to its average volume of 594,490. The stock has a fifty day moving average of $10.95 and a two-hundred day moving average of $10.68. The firm has a market cap of $573.33 million, a price-to-earnings ratio of -4.86 and a beta of 0.67. Astria Therapeutics has a 1-year low of $4.97 and a 1-year high of $16.90.

Hedge Funds Weigh In On Astria Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ATXS. Quest Partners LLC boosted its position in shares of Astria Therapeutics by 3,310.6% during the 2nd quarter. Quest Partners LLC now owns 3,206 shares of the biotechnology company’s stock valued at $29,000 after acquiring an additional 3,112 shares during the last quarter. PDT Partners LLC bought a new stake in Astria Therapeutics during the third quarter valued at approximately $140,000. SG Americas Securities LLC purchased a new position in Astria Therapeutics in the 3rd quarter worth approximately $155,000. Hsbc Holdings PLC bought a new position in shares of Astria Therapeutics in the 2nd quarter worth $171,000. Finally, Price T Rowe Associates Inc. MD purchased a new stake in shares of Astria Therapeutics during the 1st quarter valued at $200,000. 98.98% of the stock is currently owned by hedge funds and other institutional investors.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.